Nuclear β-catenin is a molecular feature of type I endometrial carcinoma

Journal of Pathology

Volumn 201, Issue 3, 2003, Pages 460-465

  Scholten, A N ^a   Creutzberg, C L ^a   van den Broek, L J C M ^a   Noordijk, E M ^a   Smit, V T H B M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

catenin; Endometrial carcinoma; Oestrogen and progesterone receptors; Proliferation rate; Wnt signalling pathway

Indexed keywords

BETA CATENIN; ESTROGEN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ESTROGEN RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; BETA CATENIN; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CYTOSKELETAL PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 0242475205     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1402     Document Type: Article

References (26)

1. Aberle H, Butz S, Stappert J, et al. Assembly of the cadherin-catenin complex in vitro with recombinant proteins. J Cell Sci 1994; 107: 3655-3663.
2. Gumbiner BM. Signal transduction of beta-catenin. Curr Opin Cell Biol 1995; 7: 634-640.
3. Aberle H, Bauer A, Stappert J, et al. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16: 3797-3804.
4. Orford K, Crockett C, Jensen JP, et al. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem 1997; 272: 24 735-24 738.
5. Kobayashi K, Sagae S, Nishioka Y. et al. Mutations of the beta-catenin gene in endometrial carcinomas. Jpn J Cancer Res 1999; 90: 55-59.
6. Fukuchi T, Sakamoto M, Tsuda H, et al. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998; 58: 3526-3528.
7. Saegusa M, Hashimura M, Yoshida T. et al. Beta-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 2001; 84: 209-217.
8. Barker N, Morin PJ, Clevers H. The Yin-Yang of TCF/beta-catenin signaling. Adv Cancer Res 2000; 77: 1-24.
9. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
10. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426.
11. Arber N, Doki Y, Han EK, et al. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 1997; 57: 1569-1574.
12. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999; 96: 5522-5527.
13. Mirabelli-Primdahl L, Gryfe R, Kim H, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999; 59: 3346-3351.
14. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17.
15. Kurman RJ (ed). Blaustein's Pathology of the Female Genital Tract: Endometrial Carcinoma (4th edn). Springer-Verlag: New York, 1994; 439-486.
16. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995; 26: 1268-1274.
17. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997; 150: 177-185.
18. Palacios J, Catasus L, Moreno-Bueno G, et al. Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. Virchows Arch 2001; 438: 464-469.
19. Scholten AN, Creutzberg CL, Noordijk EM, et al. Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system. Int J Radiat Oncol Biol Phys 2002; 52: 1067-1074.
20. Nei H, Saito T, Yamasaki H, et al. Nuclear localization of beta-catenin in normal and carcinogenic endometrium. Mol Carcinog 1999; 25: 207-218.
21. Schlosshauer PW, Pirog EC, Levine RL, et al. Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Mod Pathol 2000; 13: 1066-1071.
22. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32: 569-577.
23. Saegusa M, Okayasu I. Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol 2001; 194: 59-67.
24. Kirchner T, Brabletz T. Patterning and nuclear beta-catenin expression in the colonic adenoma-carcinoma sequence. Analogies with embryonic gastrulation. Am J Pathol 2000; 157: 1113-1121.
25. Verbeek S, Izon D, Hofhuis F, et al. An HMG-box-containing T-cell factor required for thymocyte differentiation. Nature 1995; 374: 70-74.
26. Prall OW, Rogan EM, Musgrove EA, et al. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle re-entry. Mol Cell Biol 1998; 18: 4499-4508.